CDC NEWS


powered by Surfing Waves


Latest News


COVID-19 Infected Many More Americans in 2020 than Official Tallies Show


07 Sep 2021

At the end of last year, you may recall hearing news reports that the number of COVID-19 cases in the United States had topped 20 million. While that number came as truly sobering news, it also likely was an underestimate. Many cases went undetected due to limited testing early in the year and a large number of infections that produced mild or no symptoms. Now, a recent article published in Nature offers a more-comprehensive estimate that puts the true number of infections by the end of 2020 at more than 100 million [1]. That’s equal to just under a third of the U.S. population of 328 million. This revised number shows just how rapidly this novel coronavirus spread through the country last year. It also brings home just how timely the vaccines have been—and continue to be in 2021—to protect our nation’s health in this time of the pandemic.


Vaccines prevented up to 140,000 COVID-19 deaths in U.S.


24 Aug 2021

Three highly effective COVID-19 vaccines are available in the U.S. These vaccines have been shown to slow the spread of the virus and reduce COVID-19 deaths. About half of the population has been fully vaccinated as of August 2021. But vaccination rates have varied across the country, with some states proceeding much faster than others.


U.S. to Advise Boosters for Most Americans 8 Months After Vaccination


18 Aug 2021

The Biden administration has decided that most Americans should get a coronavirus booster vaccination eight months after they received their second shot, and could begin offering third shots as early as the third week of September, according to administration officials familiar with the discussions.


How gut microbes could drive brain disorders


13 Aug 2021

Scientists are starting to work out how the gut microbiome can affect brain health. That might lead to better and easier treatments for brain diseases.


F.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems


12 Aug 2021

The decision to expand the emergency use of both the Pfizer-BioNTech and Moderna vaccines is meant to help transplant recipients and others whose immune systems are similarly compromised.




Articles


Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3


10 May 2022

Older patients in Israel who received a fourth dose of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine were more than 3 times less likely to develop severe COVID-19 than those who received only 3 doses. But while protection against severe disease did not wane during the testing period, protection against confirmed infection appeared short-lived.




Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19


20 Apr 2022

Risk of SARS-CoV-2 reinfection among unvaccinated people with prior COVID-19 is a subject of debate.1,2 We performed a survival analysis in a large US population to assess the degree and duration of protection associated with natural immunity in unvaccinated individuals.




Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster


12 Apr 2022

The risk of adolescents developing myocarditis is lower after a booster dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine than after the second dose, according to a CDC analysis of data from the Vaccine Adverse Event Reporting System (VAERS). Myocarditis is a rare but serious adverse event associated with COVID-19 mRNA vaccination. To assess whether this adverse event was also associated with booster doses administered to adolescents, the authors analyzed reports submitted to the VAERS system and v-safe between December 9, 2021, and February 20, 2022.




Even Mild COVID-19 May Change the Brain


23 Mar 2022

Alarge study comparing brain scans from the same individuals before and after SARS-CoV-2 infection suggests that brain changes could be a lingering outcome of even mild COVID-19. Writing in Nature, researchers at Oxford University’s Wellcome Centre for Integrative Neuroimaging reported that several months after study participants had SARS-CoV-2 infections, they had more gray matter loss and tissue abnormalities, mainly in the areas of the brain associated with smell, and more brain size shrinkage than participants who hadn’t been infected with the virus.




Risks and burdens of incident diabetes in long COVID: a cohort study


21 Mar 2022

Background There is growing evidence suggesting that beyond the acute phase of SARS-CoV-2 infection, people with COVID-19 could experience a wide range of post-acute sequelae, including diabetes. However, the risks and burdens of diabetes in the post-acute phase of the disease have not yet been comprehensively characterised. To address this knowledge gap, we aimed to examine the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection. Interpretation In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era. Post-acute COVID-19 care should involve identification and management of diabetes.




Enroll for Free